Plasma 16:0 ceramide as a marker of cardiovascular risk estimated by carotid intima-media thickness in people with type 2 diabetes.

Fiche publication

Date publication

mai 2024

Journal

Diabetes & metabolism

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DUVILLARD Laurence , Pr PETIT Jean-Michel , Pr VERGES Bruno , Dr PAIS DE BARROS Jean-Paul

Tous les auteurs :
Denimal D, Duvillard L, Béland-Bonenfant S, Terriat B, Pais-de-Barros JP, Simoneau I, Rouland A, Houbachi L, Bouillet B, Vergès B, Petit JM

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38710301

Résumé

- New tools are required to better assess cardiovascular risk in individuals with type 2 diabetes mellitus (T2DM). Plasma ceramides emerge as promising candidates, given their substantial influence on the pathogenesis of both T2DM and atherosclerosis. The current study aimed to investigate whether plasma ceramides in patients with T2DM are a predictive factor for carotid intima-media thickness (CIMT), a well-established noninvasive marker for atherosclerosis that predicts adverse cardiovascular outcomes.